hydroxyethyl starch
Trade name: voluven
Small moleculeexperimental
Pentastarch is a subgroup of hydroxyethyl starch, with five hydroxyethyl groups out of each 11 hydroxyls, giving it approximately 50% hydroxyethylation. This compares with tetrastarch at 40% and hetastarch at 70% hydroxyethylation, respectively. — Wikipedia
Clinical trial activity
133 trials · 154 clinical orgs · 1 marketing orgs
Phase 1
12
Phase 2
29
Phase 3
20
Phase 4
42
Earliest trial started Apr 1, 2002 (NCT00199706)
Timeline
Indications
Approved for
Studied for
- Acute Lung Injury · Phase 3
- Aged · Phase 4
- Anesthesia · Phase 4
- Anesthesia, Epidural · Phase 4
- Anesthesia, Obstetrical · Phase 4
- Anesthesia, Spinal · Phase 4
- Angina Pectoris · Phase 2
- Angina, Unstable · Phase 2
- Arthroplasty, Replacement, Hip · Phase 4
- Blood Coagulation · Phase 4
- Blood Loss, Surgical · Phase 4
- Blood Pressure · Phase 3
- Body Fluids · Phase 4
- Brain Diseases · Phase 2
- Breast Diseases · Phase 4
- Burns · Phase 4
- Cardiopulmonary Bypass · Phase 4
- Cesarean Section · Phase 4
- Chronic Limb-Threatening Ischemia · Phase 2
- Colitis, Ulcerative · Phase 3
- Colonic Neoplasms · Phase 3
- Colonic Polyps · Phase 3
- Colorectal Surgery · Phase 4
- Coronary Artery Bypass · Phase 4
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 4
- Critical Care · Phase 3
- Crohn Disease · Phase 3
- Cystic Fibrosis · Phase 2
- Diverticulitis · Phase 3
- Edema · Phase 2
- Extracorporeal Circulation · Phase 3
- Fertilization in Vitro · Early Phase 1
- Fluid Therapy · Phase 4
- General Surgery · Phase 4
- Healthy Volunteers · Phase 1
- Heart Valve Diseases · Phase 3
- Hemorrhage · Phase 4
- Hemostasis · Phase 4
- Hip Fractures · Phase 3
- HIV · Phase 1
- HIV Infections · Phase 1
- Hydroxyethyl Starch Derivatives · Phase 4
- Hypotension · Phase 4
- Hypovolemia · Phase 3
- Intestinal Polyps · Phase 3
- Intra-Abdominal Hypertension · Phase 4
- Intraoperative Complications · Phase 4
- Ischemia · Phase 3
- Kidney Neoplasms · Phase 4
- Myocardial Infarction · Phase 2
- Organ Dysfunction Scores · Early Phase 1
- Osteoarthritis · Phase 4
- Ovarian Diseases · Early Phase 1
- Pancreatic Neoplasms · Phase 4
- Pancreaticoduodenectomy · Phase 3
- Parturition · Phase 4
- Perioperative Medicine · Phase 4
- Peripheral Vascular Diseases · Phase 2
- Plasma · Phase 4
- Polyps · Phase 4
- Postoperative Complications · Phase 4
- Postoperative Hemorrhage · Phase 3
- Prostatic Neoplasms · Phase 4
- Pulmonary Edema · Early Phase 1
- Rectal Neoplasms · Phase 3
- Rectum · Phase 1
- Renal Insufficiency · Phase 4
- Respiratory Distress Syndrome · Phase 3
- Risk Factors · Phase 1
- Sepsis · Phase 4
- Shock, Septic · Phase 4
- Subarachnoid Hemorrhage · Phase 4
- Thoracic Surgery · Phase 4
- Thyroidectomy · Phase 4
- Traumatology · Phase 4
- Tuberculosis · Early Phase 1
- Urologic Surgical Procedures · Phase 4
- Vascular Diseases · Phase 2
Mechanism of action
- Unspecified targetOTHER
Plasma volume expansion
- Unspecified targetOTHER
Expansion of plasma volume
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPentastarch ↗
- ChEMBLCHEMBL2108701 ↗
- ChEMBLCHEMBL2108448 ↗
- ChEMBLCHEMBL2108122 ↗
- WikipediaHydroxyethyl starch ↗
Also known as
- 2-hydroxyethyl cellulose ether
- 2-hydroxyethyl cellulose ether
- aldiamed
- asl-607
- asl-607
- cellulose, 2-hydroxyethyl ether
- cellulose hydroxyethylate
- cellulose hydroxyethylate
- cellulose hydroxyethyl ether
- cellulose hydroxyethyl ether
- haes
- haes
- hes
- hes
- hes 130-0.4
- hes 130/0.4
- hes 130/0.4
- hespan
- hespan
- hetastarch
- hetastarch
- hetastarch
- hetastarch
- hydroxyehtyl starch
- hydroxyethylcellulose
- hydroxyethylcellulose
- hydroxyethylcellulose
- hydroxyethylcellulose
- hydroxyethyl cellulose
- hydroxyethyl cellulose
- hydroxyethyl cellulose
- hydroxyethylcellulose, sodium salt
- hydroxyethylstarch
- hydroxyethylstarch
- hydroxyethylstarch
- hydroxyethyl starch
- hydroxyethyl starch
- hydroxyethyl starch
- hydroxyethyl starch 130/0.4
- hydroxyethyl starch 130/0.4
- hydroxyl ethyl cellulose
- infukoll
- lacrigel
- minims artificial tears
- natrosol 250
- pentaspan
- pentaspan
- pentaspan
- pentastarch
- pentastarch
- pentastarch
- pentastarch
- tetraspan
- volulyte
- voluven
- voluven
- voluven
- voluven
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07307599 | Phase 4 | Jan 1, 2026 | Alnas Hospital |
| NCT06663254 | Phase 4 | Nov 30, 2024 | Central South University |
| NCT06664320 | N/A | Oct 28, 2024 | Konkuk University |
| NCT05728645 | N/A | Jul 12, 2023 | Ningbo No. 2 Hospital, Xijing Hospital |
| NCT05475886 | N/A | Jan 1, 2023 | Ningxia Medical University |
| NCT05505708 | Early Phase 1 (Phase 1) | Dec 5, 2022 | Cairo University |
| NCT05475990 | N/A | Sep 1, 2022 | Ningxia Medical University |
| NCT05435573 | N/A | Aug 17, 2022 | Mansoura University |
| NCT04465539 | N/A | Jul 15, 2020 | Tanta University |
| NCT04432675 | Phase 4 | Jun 15, 2020 | Capital Medical University |
| NCT03465943 | Early Phase 1 (Phase 1) | Mar 31, 2018 | Assiut University |
| NCT03306914 | N/A | Oct 15, 2017 | Cairo University |
| NCT03350217 | Phase 4 | Oct 9, 2017 | Indiana University |
| NCT03252496 | N/A | Aug 19, 2017 | Mansoura University |
| NCT03420261 | Phase 4 | Aug 1, 2017 | University Clermont Auvergne |
| NCT03048162 | N/A | Feb 13, 2017 | Gaziosmanpasa University |
| NCT02726620 | N/A | Jan 1, 2017 | Utrecht University, Vanderbilt University |
| NCT03249298 | N/A | Dec 1, 2016 | University of Ljubljana |
| NCT02955641 | N/A | Nov 1, 2016 | Tel Aviv University |
| NCT02906514 | Phase 3 | Sep 1, 2016 | University of Lyon |
Showing 20 of 133 trials
Page 1 / 7
Organizations
Research & Development (154)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fresenius | For profit | 16 | 9 | 2 | 2005 |
| B. Braun | For profit | 6 | 3 | 2 | 2003 |
| Konkuk University | Academic/Hospital | 6 | 6 | 1 | 2011 |
| University of Copenhagen | Academic/Hospital | 6 | 6 | 3 | 2008 |
| Yonsei University | Academic/Hospital | 6 | 5 | 2 | 2008 |
| CONRAD | For profit | 5 | 5 | 1 | 2009 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 5 | 1 | 1 | 2007 |
| Aarhus University | Academic/Hospital | 4 | 3 | 2 | 2008 |
| Nanjing Medical University | Academic/Hospital | 4 | 4 | 1 | 2008 |
| Cairo University | Academic/Hospital | 3 | 3 | 3 | 2012 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 1 | 2007 |
| Sangart | For profit | 3 | 3 | 2 | 2007 |
| University of Heidelberg | Academic/Hospital | 3 | 3 | 2 | 2007 |
| University of Lyon | Academic/Hospital | 3 | 2 | 2 | 2007 |
| Assiut University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Biopure Corporation | For profit | 2 | 2 | 1 | 2003 |
| CHU Brugmann | Academic/Hospital | 2 | 0 | 2 | 2007 |
| Free University of Brussels | Academic/Hospital | 2 | 2 | 2 | 2012 |
| Karolinska Institute | Academic/Hospital | 2 | 0 | 2 | 2007 |
| Mansoura University | Academic/Hospital | 2 | 2 | 1 | 2017 |
154 organizations
Page 1 / 8
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| DuPont | For profit | NDA | May 19, 1987 |